Current mainstream pharmacotherapy of glaucoma is the delivery of intraocular pressure-lowering medication via topical instillation. But, this dosage form has practical limitations due to well-known ocular barriers to drug transport. For the first time, highly efficient compound eye drop formulation is designed based on the idea of innovative glutathione-functionalized gelling materials. Our biomaterials-based ophthalmic drops can better improve drug bioavailabilityantiglaucoma efficacy than currently marketed eye drops, thereby showing future clinical translational potential.